Summary
Moracizine (ethmozine) is a phenothiazine derivative with demonstrated antiarrhythmic activity. To characterize the pharmacokinetics and material balance relationships in humans, we have given14C-moracizine·HCl as a single oral dose of 500 mg (50 μCi) to six healthy men. Plasma, urine, and faecal samples were collected for 7 days after administration and the concentrations of total radioactivity and intact moracizine were determined by liquid scintillation counting and HPLC, respectively.
Urine and faecal recovery accounted for 95% of the administered radioactivity. Most of this radioactivity was found in the faeces (59%). Only 0.05% of the dose was recovered from urine as intact moracizine.
The Cmax and AUC for moracizine equivalents of total radioactivity were 4- and 18-fold higher, respectively, than the corresponding values for intact moracizine. Additionally, both the disappearance of total radioactivity from plasma and its excretion rate into urine were slower in comparison to intact drug. Terminal t1/2 values calculated from plasma concentration-time data were 85.2 and 3.5 h for total radioactivity and intact moracizine, respectively. However, based on urinary excretion rates, the t1/2 for total radioactivity was shorter (29.3 h) while the t1/2 for intact drug was comparable (2.7 h) to the results obtained from the plasma data. The oral plasma clearance of moracizine was relatively large (2.2l·min−1), suggesting first-pass metabolism. The estimated oral systemic availability of moracizine was 34%.
Similar content being viewed by others
References
Morganroth J, Orth DW, Michelson EL, Dunkman WB, Pearlman AS, Horowitz LN, Josephson ME, Kastor JA (1978) Comparative antiarrhythmic efficacy and tolerance of ethmozin and quinidine. Circulation 57/58 [Suppl. II]: 103
Morganroth J, Pearlman AS, Dunkman WB, Horowitz LN, Josephson ME, Michelson EL (1979) Ethmozin: A new antiarrhythmic agent developed in USSR. Efficacy and tolerance. Am Heart J 98: 621–628
Podrid PJ, Lyakishev A, Lown B, Mazur N (1980) Ethmozin, a new antiarrhythmic drug for suppressing ventricular premature complexes. Circulation 61: 450–457
Pratt CM, Yepsen SC, Taylor AA, Mason DT, Miller RR, Quinones MA, Lewis RA (1983) Ethmozine suppression of single and repetitive ventricular premature depolarizations during therapy: Documentation of efficacy and long-term safety. Am Heart J 106: 85–91
Pratt CM, Young JB, Francis MJ, Taylor AA, Norton HJ, English L, Mann DE, Kopelen H, Quinones MA, Roberts R (1984) Comparative effect of disopyramide and ethmozine in suppressing complex ventricular arrhythmias by use of a double-blind, placebo-controlled, longitudinal crossover design. Circulation 69: 288–297
Piotrovskii VK, Merkulova IN, Romina NN, Metelitsa VI (1982) Pharmacokinetics of ethmozine after a single intravenous injection [English translation]. Kardiologiya 22: 75–80
Piotrovskii VK, Romina NN, Merkulova IN, Kurbanov, RD, Metelitsa VI, Mazar NA (1983) Bioavailability of ethmozine with oral administration [English translation]. Khim Farm Zh 221: 912–916
MacFarland RT, Moeller VR, Pieniaszek HJ Jr, Whitney CC, Jr, Marcus FI (1985) Assessment of the potential pharmacokinetic interaction between digoxin and ethmozine. J Clin Pharmacol 25: 138–143
Biollaz JB, Shaheen O, Wood AJJ (1985) Cimetidine inhibition of ethmozine metabolism. Clin Pharmacol Ther 37: 665–668
Vikhlyaev YI, Zherdev VP, Gritsenko AN, Ermakova ZI (1977) Features of ethmozine metabolism [English translation]. Farmakol Toksikol 40: 19–22
Whitney CC, Weinstein SH, Gaylord JC (1981) High-performance liquid chromatographic determination of ethmozin in plasma. J Pharm Sci 70: 462–463
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
Lam FC, Hung CT, Perrier DG (1985) Estimation of variance for harmonic mean half-lives. J Pharm Sci 72: 229–231
Schaaf LJ, Lam FC, Perrier DG (1986) Comparison of harmonic mean versus arithmetic mean clearance values. J Pharm Sci 75: 427–429
Greenway CV, Stark RD (1971) Hepatic vascular bed. Physiol Rev 51: 23–65
Dubois D, Dubois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17: 863–871
Rowland M, Tozer TN (1980) Clinical pharmacokinetics — concepts and applications, Lea and Febiger, Philadelphia
Hollister LE (1983) Antipsychotic drugs. In: Clinical pharmacology of psychotherapeutic drugs, 2nd edn. Churchill Livingstone, New York
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Howrie, D.L., Pieniaszek, H.J., Fogoros, R.N. et al. Disposition of moracizine (ethmozine) in healthy subjects after oral administration of radiolabelled drug. Eur J Clin Pharmacol 32, 607–610 (1987). https://doi.org/10.1007/BF02455996
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02455996